Citadel Advisors
NMRD

Citadel Advisors’s Nemaura Medical, Inc. Common Stock NMRD Stock Holding History

Citadel Advisors’s Portfolio NMRD Stock Details NMRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-28,900
Closed -$299K – 14917
2021
Q2 		$299K Buy
28,900
+10,700
+59% +$102K ﹤0.01% 11289
2021
Q1 		$139K Buy
+18,200
New +$120K ﹤0.01% 12139

Other funds holding NMRD

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Citadel Advisors's NMRD Position: Q1 2024 in Review

Citadel Advisors sold out of Nemaura Medical, Inc. Common Stock (NMRD) in Q1 2024, closing a stake of 41,693 shares — an estimated $9.38K sold.

Citadel Advisors first reported a position in NMRD in Q2 2018 and held it in 6 quarters. The position peaked at $85K in Q3 2020. 2 funds tracked by Wall St. Rank hold NMRD as of Q1 2024.

  • Citadel Advisors reported no remaining Nemaura Medical, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 41,693 Nemaura Medical, Inc. Common Stock shares in Q1 2024, an estimated $9.38K.
  • Citadel Advisors first reported a position in Nemaura Medical, Inc. Common Stock in Q2 2018 and held it in 6 quarters.
  • Citadel Advisors's Nemaura Medical, Inc. Common Stock position peaked at $85K in Q3 2020.
  • 2 funds tracked by Wall St. Rank held Nemaura Medical, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.